J Med Screen 2008;15:207-210
doi:10.1258/jms.2008.008057
© 2008 Medical Screening Society
Consensus recommendations for cervical cancer prevention in the Czech Republic: a report of the International Conference on Human Papillomavirus in Human Pathology (Prague, 1–3 May 2008)
Ruth Tachezy
,
National Reference Laboratory for Papillomaviruses, Department of Experimental Virology, Institute of Haematology and Blood Transfusion, Prague, Czech Republic
Philip Davies
,
European Cervical Cancer Association, Brussels, Belgium
Marc Arbyn
,
Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium; ECCG (European Cooperation on development and implementation of Cancer screening and prevention Guidelines), IARC, Lyon, France
Lukás Rob
,
Department of Oncogynaecology, Second Medical Faculty, Obstetrics and Gynaecology Clinic, Charles University, Prague, Czech Republic
Gunta Lazdane
,
WHO Regional Office for Europe, Copenhagen, Denmark
Jana Petrenko
,
Coalition for Health, Prague, Czech Republic
Eva Hamsíková
,
National Reference Laboratory for Papillomaviruses, Department of Experimental Virology, Institute of Haematology and Blood Transfusion, Prague, Czech Republic
Alena Beková
,
Centre of Gynaecology-Oncology Prevention, Prague, Czech Republic
Jan Klozar
,
Department of Otolaryngology Head and Neck Surgery, First Medical Faculty, Charles University, Prague, Czech Republic
Jaroslava Dusková
,
Institute of Pathology, First Medical Faculty and Chair of Pathology Institute of Postgraduate Studies, Prague, Czech Republic
Correspondence to: Ruth Tachezy, National Reference Laboratory for Papillomaviruses, Department of Experimental Virology, Institute of Haematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague, Czech Republic; rutach{at}uhkt.cz
A comparison of cervical cancer incidence and mortality in the
Czech Republic with that from other countries shows that the
burden of cervical cancer here is considerably higher than in
Western Europe, where screening is widespread. In May 2008,
the International Conference on Human Papillomavirus in Human
Pathology was convened to review the latest evidence and to
formulate consensus recommendations for the reduction of cervical
cancer rates. The Czech Republic is spending considerable resources
on cervical cancer prevention, but these resources are being
used inefficiently. The current system is characterized by a
lack of coordination and monitoring that leads to the over-screening
of a minority of women while the majority of the target population
are under-screened or not screened at all. It was recommended
that a comprehensive, organized programme be implemented, coordinated
by an independent administrative body with legal and budgetary
responsibility. As the laboratory infrastructure and professional
technical skills required for a quality-assured organized screening
programme are already in place, implementation of this programme
would not require much in the way of additional resources to
produce substantial cost-effective reductions in cervical cancer
rates.
 |
INTRODUCTION
|
|---|
Cervical cancer remains a serious public health problem in the
Czech Republic. As the sixth most common cancer in Czech women,
it represents a substantial, but unnecessary burden on the Czech
population. Comparison of the Czech incidence and mortality
data with databases recently compiled at the European level
reveals that the burden of cervical cancer in the Czech Republic
is considerably higher than in Western European countries where
screening is widespread (Table
1, Figure
1).
1,2
View this table:
[in this window]
[in a new window]
|
Table 1 Incidence and mortality from cervical cancer (corrected for NOS): number of cases or deaths, crude and standardized rates and cumulative rates up to the age of 74 years; for 2004, in parts of the European Union and the Czech Republic
|
|
View larger version (20K):
[in this window]
[in a new window]
|
Figure 1 Age-standardized rates of incidence and mortality from cervical cancer (/100,000 women-years) in the 10 member states that joined the European Union in 2004, ranked by increasing mortality, estimates for 2004 (direct standardization using the world reference population). Source: ÚZIS CR, NOR CR 2006,4 Slovenia (Slovenian Cancer Registry 2003), other member states1,2
|
|
|
HISTORY OF CERVICAL CANCER SCREENING
|
|---|
The Czech Republic was one of the first countries in the world
to introduce cervical cancer screening based on the Pap smear
in 1947 and it was also one of the first to make it widely available
to women when in 1966 the Czech Republic parliament enacted
legislation allowing all women to have a free annual gynaecological
examination that included a Pap smear.
3 As a result of these
measures, the incidence of cervical cancer decreased steadily
from 32 cases/100,000 women in 1960 to 21/100,000 in 1990.
4 Since then, the incidence rate has remained stable at this level
in spite of increased availability of opportunistic screening.
Coverage of women in the screening age (30–59 years) is
estimated at 35%.
5 In contrast, organized screening programmes
with direct invitation of women and full quality assurance at
all levels have been shown to provide the maximum reductions
in cervical cancer rates, to provide the most equitable coverage
of the population and to make the most cost-effective use of
health-care resources.
6–10
To date, the accepted standard for cervical screening has been the Pap test. However, new technologies such as testing for human papillomaviruses (HPV) and HPV vaccination have been demonstrated to be highly effective in reducing cervical cancer precursors.11–17 Therefore, modern and sustainable programmes for cervical cancer prevention must now consider the integration of these technologies based on these data, together with a full assessment of national cost-effectiveness analyses, health-care priorities and budgets.
In recognition of these issues, the International Conference on Human Papillomavirus in Human Pathology18 was convened to bring relevant Czech experts, including members of the Working Group for the Cervical Cancer Screening of the Czech Ministry of Health, together with their international colleagues to review the latest evidence on cervical cancer prevention and to incorporate these data into consensus recommendations for the implementation of a modern cervical cancer prevention programme.
|
EXISTING INFRASTRUCTURE IN THE CZECH REPUBLIC
|
|---|
Recommendations for the implementation of an organized cervical
cancer prevention programme in the Czech Republic must take
into account the existing infrastructure that will form the
foundation for that programme. This infrastructure includes:
- Existence of a national unique personal identification number that can be used as the basis for an invitational screening programme;
- A national cancer registry established in 1976, is recognized by the International Association of Cancer Registries and can participate in quality assurance and programme evaluation;
- Sufficient Pap test processing capacity for a national organized programme through a network of some 50 cytology laboratories that all use the Bethesda cytology classification system as recommended in European guidelines;19,20
- Sufficient clinical capacity for the follow-up of women with abnormal cytology through a nationwide network of some 1500 gynaecologists trained and equipped for cervical screening, as well as diagnosis and treatment of screen-detected cervical intraepithelial neoplasia;
- A national colposcopy training programme with expert certification;
- Recommendations for management of women with precancerous lesions or cervical cancer, which is in accordance with European guidelines;21
- A network of 30 HPV testing laboratories with an established national quality assurance programme;22
- An internationally recognized National Reference Laboratory for Papillomaviruses which is a member of the International Network of Quality Assurance (QA) in HPV testing and which administers the Czech national HPV QA programme;22
- The Institute of Biostatistics and Analysis which already administers the screening registries for breast and colorectal cancer and which could easily be expanded to include a cervical cancer screening registry.
Therefore, many essential elements of an organized cervical cancer screening programme as set-out in the European Guidelines for Quality Assurance in Cervical Cancer Screening are already in place, but there remains a need to ensure an effective coordination and quality control of these elements.
|
CONSENSUS RECOMMENDATIONS OF THE INTERNATIONAL CONFERENCE ON HUMAN PAPILLOMAVIRUS IN HUMAN PATHOLOGY FOR CERVICAL CANCER PREVENTION IN THE CZECH REPUBLIC
|
|---|
Recognizing the infrastructure existing in the Czech Republic,
the International Conference on Human Papillomavirus in Human
Pathology recommends the following steps be undertaken to complete
the implementation of a cost-effective organized cervical screening
programme:
- To set up a central administrative structure with overall legal and budgetary responsibility for:
- Establishing the screening policy;
- Integrating the components involved in the implementation of the programme;
- Monitoring the quality and the performance of the programme;
- To allocate sustained financial resources that are sufficient to cover all components of the screening process through a specific item in the Ministry of Health budget;
- To provide effective, efficient and legally sanctioned access to a current population-based database to be used for programme recruitment;
- To establish a centralized registry including individual linkages to cervical cytology, colposcopy, histology and HPV test results to be used for call–recall, tracking of screen-positives, programme monitoring and QA purposes;
- To provide effective and efficient access to a cancer registry for programme audit including the confidential audit of screening histories of women with cervical cancer;
- Where they do not already exist, to establish training standards, professional guidelines and performance indicators for each stage in the screening process in accordance with scientific evidence and international benchmarks;
- To establish legally binding QA regulations and procedures to form an integrated QA policy covering the entire screening process from initial recruitment to the follow-up and management of women with cervical disease;
- To establish educational programmes and resources for the general public and health-care professionals with dedicated budgets for their execution;
- To establish mechanisms to identify and invite under-screened and unscreened women;
- To define a population-based HPV vaccination strategy that is fully integrated within the screening programme in order to be able to distinguish vaccinated cohorts from non-vaccinated cohorts and to assess the effects of vaccination a vaccination registry must be created that is linkable to the screening and cancer registry;
- To implement a randomized health policy evaluation to properly assess the logistics of using HPV testing as a primary screening test within the Czech screening programme.
The Czech Republic is spending considerable resources on cervical cancer prevention, but these resources are being used inefficiently. Implementing the remaining elements of an organized screening programme would inevitably produce substantial reductions in cervical cancer rates while saving money for the Czech health-care system.
|
ACKNOWLEDGEMENTS
|
|---|
The authors are grateful to the invited speakers (listed in
alphabetical order): Ahti Anttila (Finland), Christine Bergeron
(France), Gary Clifford (France), Carl Chow (UK), Joakim Dillner
(Sweden), Lena Dillner (Sweden), Magdalena Grce (Croatia), Lalle
Hammarstedt (Sweden), Amanda Herbert (UK), Ivan Hirsch (France),
Ole Erik Iversen (Norway), Joseph Jordan (UK), Kate
ina Lehovcová
(Czech Republic), Ladislav Masák (Slovakia), Chris Meijer
(Netherlands), Michael Pawlita (Germany), Marek Pluta (Czech
Republic), Charles Redman (UK), Peter J.F. Snijders (Netherlands),
Marek Spaczynski (Poland), Stina Syrjanen (Finland), Sjoerd
van der Burg (Belgium), Maja
akelj (Slovenia) as well as to
the participants of the International Workshop on Human Papillomavirus
and Consensus Recommendations for Cervical Cancer Prevention
coming from Austria, Belgium, Bosna and Herzegovina, Brazil,
Croatia, the Czech Republic, Denmark, Finland, France, Germany,
Greece, Hungary, Ireland, Italy, the Republic of Korea, Mexico,
the Netherlands, Norway, Poland, Portugal, Romania, the Federation
of Russia, Serbia and Montenegro, Slovakia, Slovenia, Spain,
Sweden, Switzerland, Thailand, Tunisia, Turkey, the UK and the
USA for their active contribution in the final agreement of
these recommendations.
This work was supported by a grant NR/8852-3/2006 from the Ministry of Health of the Czech Republic.
Accepted for publication September 5, 2008.
|
REFERENCES
|
|---|
- Arbyn M, Raifu AO, Autier P, et al. Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 2007;18:1708–15[Abstract/Free Full Text]
- Arbyn M, Autier P, Ferlay J. Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Ann Oncol 2007;18:1425–7[Free Full Text]
- Herold J, Luksch F. Cytodiagnostika rakoviny rodidel. Státní zdravotnické nakladatelství, Praha, 1954. [Czech]**
- Cancer Incidence in the Czech Republic 2004, ÚZIS CR, NOR CR 2006**
- Tachezy R, Rob L. Screening for prevention of cervical cancer in the Czech Republic (Czech). Casopis Lekaru Ceskych 2007;146:939–44[Medline]
- Nieminen P, Kallio M, Anttila A, et al. Organised vs. spontaneous Pap-smear screening for cervical cancer: a case-control study. Int J Cancer 1999;83:55–8[Medline]
- Borras JM, Guillen M, Sanchez V, et al. Educational level, voluntary private health insurance and opportunistic cancer screening among women in Catalonia (Spain). Eur J Cancer Prev 1999;8:427–34[Medline]
- Bos AB, van Ballegooijen M, van Gessel-Dabekaussen AA, et al. Organised cervical cancer screening still leads to higher coverage than spontaneous screening in the Netherlands. Eur J Cancer 1998;34:1598–601[Medline]
- Arblaster L, Lambert M, Entwistle V, et al. A systematic review of the effectiveness of health service interventions aimed at reducing inequalities in health. J Health Serv Res Policy 1996;1:93–103[Medline]
- Ronco G, Segnan N, Ponti A. Who has Pap tests? Variables associated with the use of Pap tests in absence of screening programmes. Int J Epidemiol 1991;20:349–53[Abstract/Free Full Text]
- Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 2005;92:1–6
- Elfgren K, Rylander E, Radberg T, et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol 2005;193(Pt 1):650–7[Medline]
- Bulkmans NW, Rozendaal L, Voorhorst FJ, et al. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer 2005;92:1800–2[Medline]
- Bulkmans NW, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94–101[Medline]
- Ronco G, Segnan N, Giorgi-Rossi P, et al. New technologies for Cervical Cancer Working Group. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006;98:765–74[Abstract/Free Full Text]
- Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271–8[Medline]
- Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247–55[Medline]
- Central Eur J Public Health 2008;16
- Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114–9[Abstract/Free Full Text]
- Herbert A, Bergeron C, Wiener H, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology. Cytopathology 2007;18:213–9[Medline]
- Rob L, Robová H, Ka
írek J, et al. Management abnormálních nález
na d
lo
ním hrdle (Czech). Moderní gynekologie a porodnictví 2003;12:665–75 - Tachezy R, Smahelova J. Quality assurance of human papillomavirus testing. Coll Antropol 2007;31(Suppl. 2):61–5
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Top
INTRODUCTION
HISTORY OF CERVICAL CANCER...
